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Paper mill-derived research has penetrated biomedical litera-
ture, and it is affecting the integrity and reliability of research 
[1]. The use of paper mills (i.e., pay-to-create services) is an act 
of misconduct if the use of such services is not declared since 
it gives the false impression of the authors’ effort, input, and 
originality, when in fact none was involved; moreover authorship 
is false since the data is created or fabricated by others, and not 
generated honestly in a laboratory by the authors themselves. 
Paper mill-derived research has itself become an academic 
cancer in urgent need of a cure and solutions.
Several sleuths, anonymous and named, continue to exa-
mine cancer literature, and their efforts may or may not be 
related to the cancer reproducibility project by the Center for 
Open Science. Independent of the source of these discoveries, 
the discoveries themselves are cause for concern and alarm. 
In the most recent paper mill exposé, which may or may not 
be related to other paper mills, three papers are highlighted in 
this letter: Hu et al. (2018), Pan et al. (2019), and Liu et al. (2020) 
[2–4]. What is curious about these papers was the discovery of 
breast cancer in males (Hu et al. [2]), ovarian cancer in males 
(Liu et al. [4]), and prostate cancer in females (Pan et al. [3]). 
In all three studies, genders were described as binary, i.e., 
exclusively biological male and female, and none of the study 
subjects were indicated as being transgender, which might 
be associated with altered hormone levels [5] and thus the 
possibility of confusing genders.
While it is not unusual to discover breast cancer in males, 
it is a very rare (about 1% of all cases of breast cancer) pheno-
menon [6]. Despite this, Hu et al. [2] reported a >59% incidence 
of breast cancer in males (38/64 subjects), apparently detected 
using a quantitative real-time polymerase chain reaction (qRT-
-PCR) with a long non-coding RNA (lncRNA), LINC01116. Not 
only the extremely high value, but also the fact that cases in 
males were higher than in females (a potentially first extraordi-
nary finding in the cancer literature) suggest that these findings 
are too good to be true, or, in other words, false.
In Liu et al. [4], ovarian cancer was found in 28 males among 
49 subjects, i.e., >57% incidence, as apparently detected by 
LINC00675, while in Pan et al. [3], prostate cancer was found in 
27 females among 52 subjects, i.e., an almost 52% incidence, 
as apparently detected by microRNA-605-3p, both using qRT-
-PCR. In these cases, the incidence of ovarian cancer in males 
and prostate cancer in females should theoretically be 0%, 
since, evidently, biological males do not have an ovary while 
biological females do not have a prostate. Would it thus be 
safe to assume that these findings are either extraordinary, or 
that they are false? The clue may lie in the fact that Pan et al. 
(2019) has already been retracted for very opaque reasons. 
This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download 
articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
256
Its  retracted status is (unfortunately) not – but should be – 
indicated on its PubMed entry. 
This case also draws concern about the journal in which three 
papers were published – the European Review for Medical and 
Pharmacological Sciences – which has a 2019 Clarivate Analytics 
Journal Impact Factor (JIF) of 3.024 and is indexed in the Web of 
Science and PubMed. The fact that it is an open access journal 
fortifies the risk of potentially fictitious paper mill-derived cancer 
research because it is so easy to access, and thus cite. In  fact, 
a Google Scholar search for Hu et al. (2018), Pan et al. (2019), 
and Liu et al. (2020) [2–4] reveals that they have been cited 44, 
4, and 0 times, respectively. In the case of Pan et al. (2019), those 
citations could be considered to be unfair contributors to the jo-
urnal’s JIF, and the JIF itself would need to be adjusted downwards 
to account for the retracted paper’s citations [7].
This letter provides a bird’s-eye view of three papers 
among dozens or hundreds of papers on cancer with po-
tentially fabricated data and findings, most likely derived 
from one (and the same) or more paper mills that might 
have served multiple clients with recycled or fabricated data, 
including figures, tables, and text, often confusing cancer cell 
lines within and among papers. Ultimately, readers are left 
confused, doubt regarding the validity of the findings incre-
ases, and mistrust in some of the most basic elements of trust 
in biomedical and academic publishing, such as the blind 
claim of the peer review, and the quality aspect of PubMed 
[8], Clarivate Analytics and the JIF, are now on the increase.
This letter has obvious limitations: it only provides a brief 
three-paper snapshot of a potentially far-reaching problem 
regarding the integrity of peer-reviewed and indexed cancer 
literature. This letter also focuses on one issue almost exclusi-
vely, namely the improbability of prostate cancer in women, 
and ovarian and breast cancer in men, or at least at the levels 
reported by Hu et al. (2018), Pan et al. (2019), and Liu et al. (2020) 
[2–4]. There are many other issues in these related papers that 
need to be explored and discussed.
The criminality of individuals working for and supporting 
paper mills, and the networks of researchers, editors, journals, 
and publishers that may be involved, deserves heightened 
awareness and further investigation.
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